Avita Medical announces FDA approval of RECELL System for treatment of vitiligo

Avita Medical announced that the U.S. Food and Drug Administration has approved its application for premarket approval, or PMA, of its RECELL System for the treatment of vitiligo. “RECELL represents first-in-class treatment for repigmentation through the delivery of normal, healthy skin cells. This is a breakthrough approval for AVITA Medical, significantly expanding the clinical applications for RECELL, and demonstrates our continued commitment to patient care. We look forward to offering a meaningful one-time treatment option for patients with stable vitiligo across the U.S.,” said Jim Corbett, Chief Executive Officer of Avita Medical.